Novavax Inc. (NVAX) said Friday it will supply 5 million doses of its protein-based COVID-19 vaccine to Israel as part of an advance purchase agreement, with the Israeli Ministry of Health also taking an option to buy an additional 5 million doses. "Novavax will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in Israel pending regulatory approval," the company said in a statement. Novavax is currently conducting two Phase 3 trials of the vaccine involving about 30,000 participants in the U.S. and Mexico, as well as a trial involving about 15,000 people in the U.K. Data from both trials was published in the New England Journal of Medicine and showed high efficacy and safety. The vaccine has been granted conditional marketing authorization in the EU and an emergency use listing by the World Health Organization. It is currently under review by other regulatory bodies. Shares were up 0.5% premarket but have fallen 46% in the last 12 months, while the S&P 500 has gained 14%.
(END) Dow Jones Newswires
01-28-22 0814ETCopyright (c) 2022 Dow Jones & Company, Inc.